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Cysteine proteases are proteolytic enzymes involved in the degradation of pro       
structurally different groups are formed: papain-like (clan CA), ICE-like (clan CD) an          
cysteine proteases belong to the first two clans, being of particular interest for this w         
CA. Cysteine proteases are implicated in several disease processes, such as inflam        
a key role in some parasites life cycle, like falcipain from the parasite, Plasmod         
Plasmodium falciparum, expresses four cysteine proteases from clan CA, known         
interest as therapeutic targets  given their importance to the parasite life cycle [        
developed, taking in consideration the recognition sequence of peptide substrates         
ketones. This  class is very interesting since it inhibits irreversibly, cysteine protease           
the irreversible inhibition mechanism , these compounds also present a very high        
also able to inhibit serine proteases  but in a much slower pace [4]. Bearing these f         
moiety were synthesized (Figure 1) [5,6], and their activity against falcipain-2 was eva        
teins. Considering their sequence homology three
d picornain-like (clan PA(C)) [1]. The great majority of
ork, parasite cysteine proteases which belong to clan
matory and immunological disorders [2], playing also
ium falciparum, the causative agent of malaria [3].
as falcipains, being falcipain-2 and 3 of particular
3]. Several cysteine proteases inhibitors have been
and different warheads have been tested, like, diazo
s, by alkylation of the active site thiol group. Besides
specificity for cysteine proteases, although they are
acts in mind, several compounds carrying the diazo





         
 
          
                 
 
 
                
                  
                     
                  
                      
                   
                  
                  
                     
                   
                        
                     
 
 
            
 
                    
                      
                     
                 
Fig. 1. Generic scheme for the synthesis of diazo moiety 
bearing compounds (R = alkyl, aryl, peptidyl)
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